|[February 26, 2014]
Sophiris Bio to Present at the Cowen and Company 34th Annual Health Care Conference
SAN DIEGO & VANCOUVER, British Columbia --(Business Wire)--
Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a
biopharmaceutical company developing a clinical stage, targeted
treatment for the symptoms of benign prostatic hyperplasia (BPH or
enlarged prostate), today announced that Randall
E. Woods, president and chief executive officer, will present a
corporate overview at the Cowen and Company 34th Annual
Health Care Conference. The presentation is scheduled for Wednesday,
March 5, 2014 at 10:40 a.m. EST at the Marriott Copley Place in Boston,
The presentation will be webcast live and can be accessed through the
Company's Investor Relations page at www.sophiris.com.
A replay of the presentation will be available after the conclusion of
the live presentation and available on the Company's website for 90 days.
Sophiris Bio Inc. is a biopharmaceutical company developing a
clinical-stage, targeted treatment for the symptoms of benign prostatic
hyperplasia (BPH or enlarged prostate), which it believes is an
unsatisfied market with significant market potential. Sophiris' lead
candidate for BPH, PRX302, is designed to be as efficacious as
pharmaceuticals, less invasive than the surgical interventions, and
without the sexual side effects seen with existing treatments. Sophiris
initiated its first Phase 3 clinical trial of PRX302 in October 2013.
For more information, please visit www.sophiris.com.
Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from those
implied by such statements, and therefore these statements should not be
read as guarantees of future performance or results. All forward-looking
statements are based on Sophiris' current beliefs as well as assumptions
made by and information currently available to Sophiris and relate to,
among other things, anticipated financial performance, business
prospects, strategies, regulatory developments, clinical trial
enrollment and results, market acceptance and future commitments.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
press release. Due to risks and uncertainties, including the risks and
uncertainties identified by Sophiris in its public securities filings;
actual events may differ materially from current expectations. Sophiris
disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
[ Back To TMCnet.com's Homepage ]